Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Planned pivotal phase III trial of gimatecan vs topotecan in refractory patients with advanced epithelial ovarian, fallopian or peritoneal cancer, resistant or partially sensitive to platinum in China

Trial Profile

Planned pivotal phase III trial of gimatecan vs topotecan in refractory patients with advanced epithelial ovarian, fallopian or peritoneal cancer, resistant or partially sensitive to platinum in China

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimatecan (Primary) ; Topotecan
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Lees Pharmaceutical Holdings
  • Most Recent Events

    • 07 Aug 2013 A clinical trial application for this trial, given fast-track designation, has been accepted for review by the China FDA, according to a media release from Lees Pharmaceutical Holdings. The company hopes to initiate this trial in the second half of 2014.
    • 07 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top